SinnerSchrader

Stock factsheet

Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. We do not have a verified market capitalisation for this company.

Company profile

Schott Pharma is a subsidiary of Schott AG that develops and manufactures primary packaging from specialty glass and polymer for the pharmaceutical industry, including vials, syringes and cartridges. The company supplies global pharmaceutical and biotech customers with regulatory-approved packaging solutions. Schott Pharma was listed on the Frankfurt Stock Exchange in 2023.

Short profile generated automatically and checked for plausibility. A full editorial profile follows once we cover the company.

Comparable companies

Companies in the Artificial Intelligence & Software sector of a similar size.

News timeline

1. 03.08.2026 Government Satellite Contracts: What Demo Deals Mean for Space Small Caps
2. 03.08.2026 AI Security Validation: What Valuation Jumps Really Mean
3. 03.08.2026 IND Process & FDA Trialblazer: What Changes for Biotech Small Caps
4. 03.08.2026 Defense Contracts in Space: Large Corp vs. Start-Up — What Investors Should Know
5. 03.08.2026 Continuous Validation: How AI Is Reshaping the Cybersecurity Market
6. 03.08.2026 Laser Communication in Orbit: What Demonstration Contracts Mean for Space Small Caps
7. 03.08.2026 AI-Powered Security Validation: Continuous Monitoring Replaces the Annual Pentest
8. 03.08.2026 Demonstration Contracts in Orbit: What Navy Awards Mean for Space Start-Ups
9. 03.08.2026 Revenue Guidance Upgrade After Approval: What It Means for Biotech Investors
10. 03.08.2026 Pivotal Trials in Oncology: What Phase 2/3 Data Really Mean
11. 02.08.2026 AI Copyright: When Training Data Becomes a Liability Risk
12. 01.08.2026 Laser Communication in Orbit: What Military Contracts Mean for Space Small Caps
13. 31.07.2026 SRAM in the AI Era: How Niche Chips Promise Data Center Returns
14. 30.07.2026 Defense IPO Postponed: What Really Drives Valuation Expectations
15. 29.07.2026 Defense IPO Timing: Why Strong Order Backlogs Aren't Enough
16. 28.07.2026 GLP-1 for Addiction: What Phase II Trial Data Really Promise
17. 27.07.2026 FDA Reviewers vs. Sponsor: When Regulators and Biotech Read Data Differently
18. 24.07.2026 Quantum Correction: Valuation Reset or Fundamental Breakdown?
19. 23.07.2026 Megacap Acquisitions in the Quantum Market: Opportunity or Displacement?
20. 22.07.2026 Framework Agreement or Firm Order? How Small-Cap Investors Read AI Deals
21. 20.07.2026 Dilution in Quantum Small Caps: How to Read a Capital Increase
22. 17.07.2026 Pump-and-Dump: How Regulation Dried Up Micro-Cap IPOs
23. 16.07.2026 Russell 2000 at Record High: Macro Signals for Small-Cap Investors
24. 15.07.2026 AI Platform Pressure: How Cybersecurity Small Caps Defend Their Niche
25. 13.07.2026 Micro-Cap Biotech: What Really Drives Share Price Losses
26. 09.07.2026 Hong Kong IPO Market: When Megadeals Crowd Out Small-Cap Listings
27. 08.07.2026 AI Infrastructure Small Caps: ARR, Margins, and Concentration Risk
28. 30.07.2026 Quantum Computing Stocks: When One Contract Moves the Market
29. 30.07.2026 FDA Adcom: What a Negative Vote Costs Biotech Investors
30. — Biotech IPOs 2026: What an Open IPO Window Really Means

Investor Relations

We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.

Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.